Literature DB >> 12222018

Multiple sclerosis and oral care.

Janice Fiske1, Janet Griffiths, Shelagh Thompson.   

Abstract

Multiple sclerosis is a complex neurological condition affecting sensory and motor nerve transmission. Its progression and symptoms are unpredictable and vary from person to person as well as over time. Common early symptoms include visual disturbances, facial pain or trigeminal neuralgia and paraesthesia or numbness of feet, legs, hands and arms. These, plus symptoms of spasticity, spasms, tremor, fatigue, depression and progressive disability, impact on the individual's ability to maintain oral health, cope with dental treatment and access dental services. Also, many of the medications used in the symptomatic management of the condition have the potential to cause dry mouth and associated oral disease. There is no cure for multiple sclerosis, and treatment focuses on prevention of disability and maintenance of quality of life. Increasingly a multi-disciplinary team approach is used where the individual, if appropriate his/her carer, and the specialist nurse are key figures. The dental team plays an essential role in ensuring that oral health impacts positively on general health.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222018     DOI: 10.12968/denu.2002.29.6.273

Source DB:  PubMed          Journal:  Dent Update        ISSN: 0305-5000


  2 in total

1.  Orofacial evaluation in patients with multiple sclerosis using Nordic Orofacial Test-Screening.

Authors:  Marcela Leticia Leal Gonçalves; Cristiane Miranda França; Yara Dadalti Fragoso; Alessandro Melo Deana; Larissa Mateus de Almeida; Sandra Kalil Bussadori
Journal:  Clin Oral Investig       Date:  2016-09-06       Impact factor: 3.573

2.  Use of a time-of-flight camera with an Omek Beckon™ framework to analyze, evaluate and correct in real time the verticality of multiple sclerosis patients during exercise.

Authors:  Gonzalo Eguíluz; María Begoña García
Journal:  Int J Environ Res Public Health       Date:  2013-11-04       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.